Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19<sup>+</sup> Tumors
Authors: Natalie S. Grover, Nicholas Tschernia, Gianpietro Dotti, Barbara Savoldo
Journal: Journal of Clinical Oncology (2021)

Article Tools REVIEW ARTICLES Immunotherapy for Hematologic Malignancies Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.01738 Journal of Clinical Oncology - published online before print January 12, 2021 PMID: 33434072 Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19+ Tumors Natalie S. Grover , MD1,2xNatalie S. GroverSearch for articles by this author; Nicholas Tschernia , MD1,2xNicholas TscherniaSearch for articles by this author; Gianpietro Dotti, MD1,3xGianpietro DottiSearch for articles by this author; and Barbara Savoldo , MD, PhD1,4xBarbara SavoldoSearch for articles by this author Show More 1Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC2Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC3Departments of Immunology and Microbiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC4Department of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, NC https://doi.org/10.1200/JCO.20.01738 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologyContextKey ObjectiveWhat are the recent advances of chimeric antigen receptor T cells (CAR-Ts) that target antigens other than CD19 in hematologic malignancies?Knowledge GeneratedChallenges of developing CAR-Ts for non–B-cell malignancies include the selection of suitable antigens, limitation of on-target/off-tumor toxicities, and complexity of the tumor microenvironment. We describe developments and future directions of CAR-T cells in multiple myeloma, Hodgkin lymphoma, T-cell malignancies, and acute myeloid leukemia.RelevanceNovel CAR-Ts for hematologic malignancies are entering the clinic, proving that this strategy holds promise for other targets and supporting future work in solid tumors.SUPPORTSupported by Lineberger Comprehensive Cancer Center, The University of North Carolina Oncology, Grant No. K12-CA120780 (N.S.G.) and by a Lymphoma Research Foundation Career Development Award. N.T. is supported by National Cancer Institute (NCI) Grant No. T32-CA211056. G.D. is supported by NCI Grants No. R01-CA193140-03, R01-CA243543-01, and R21-CA229938-01A1 and by American Association for Cancer Research Stand Up to Cancer. B.S. is supported by NCI Grants No. R01-CA247497 and U01-CA239258.AUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: Natalie S. GroverData analysis and interpretation: Natalie S. GroverManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTExtending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19+ TumorsThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Natalie S. GroverStock and Other Ownership Interests: Sangamo TherapeuticsConsulting or Advisory Role: Seattle Genetics, Tessa Therapeutics, KiteResearch Funding: GenentechUncompensated Relationships: Tessa TherapeuticsNicholas TscherniaResearch Funding: AstraZeneca, MedImmuneGianpietro DottiConsulting or Advisory Role: Molmed, Bellicum Pharmaceutical, Tessa TherapeuticsResearch Funding: Bellicum Pharmaceuticals, Cell MedicaPatents, Royalties, Other Intellectual Property: Patents in the field of T/NKT-cell therapies and royalties derived from licensed patents.Barbara SavoldoConsulting or Advisory Role: Tessa TherapeuticsResearch Funding: Cell Medica, bluebird bio, Bellicum Pharmaceuticals, Tessa TherapeuticsPatents, Royalties, Other Intellectual Property: Patent filed for some CAR molecules (I)No other potential conflicts of interest were reported.